Smith & Nephew SNATS Inc (SNN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Smith & Nephew SNATS Inc stock $30.19, price $31.15, that is 3.1% below the price, quality 63 out of 100. Rating: fairly valued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $19.43 – $37.36 · fair‑value band $18.71 – $41.16 · the $31.15 price screens above the $30.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Smith & Nephew SNATS in your weekly email
Every Wednesday you see whether Smith & Nephew SNATS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Show moreShow less
It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints.
In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions.
Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems.
It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Stock analysis
Smith & Nephew SNATS Inc (SNN) currently trades at $31.15, while our model-based Fair Value estimate is $30.19, so the stock looks roughly fairly valued today (gap 3.2%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $32.73 per share, and 8 of the 25 models we run sit above the $31.15 price.
Bear case: the Dividend Discount group reads lowest at $13.99, and 17 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: $18.71 (bear) to $41.16 (bull), the price of $31.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Smith & Nephew SNATS Inc reported revenue of $6.2B in FY2025 versus $5.2B in FY2021, a compound +4.3%/yr. Reported net income was $626M in FY2025, compounding +4.6%/yr from FY2021.
Key figures
Market cap $13.4B Large · P/E ratio 21.2 · P/S ratio 2.15 · EPS (TTM) $1.47 · Dividend yield 1.3% · Net margin 10.1% · Return on equity 11.9% · Return on assets (EBIT) 5.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 19% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −3%, SNN screens cheaper than that median.
Fair Value models
Bear$18.71Fair Value $30.19Bull$41.16
Price $31.15 · Downside -3.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.9172 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Start year 2020 (pandemic). Over 10 years: +2.9% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+6.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.6%
Dividend (yield on the price)1.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.7% vs 2.6%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 16%
2025 sits 53% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.6% a year for the price and +2.2% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
AI conclusion: The business shows strength through its CARTIHEAL implant with clear clinical advantages in cartilage repair yet remains limited by average positioning, moderate margins and no evident durable moat.
Main risk: Stryker's Mako robotic system and Triathlon implants could capture more market share from Smith & Nephew's CORI platform and knee products, pressuring prices and margins in orthopaedics and sports medicine.
Bull case: By launching differentiated products like the Landmark knee and expanding CARTIHEAL adoption, the company could regain share in key segments despite rival pressure.
Bear case: If established rivals like Stryker maintain their installed base advantage in robotics, Smith & Nephew might see persistent underperformance in orthopaedics leading to slower overall growth.
Smith+Nephew has rolled out its CARTIHEAL cartilage repair implant across initial European markets with five-year trial results showing clear advantages over standard procedures. First-half underlying revenue growth however remained well below the company's own targets. Will the new products deliver the needed acceleration in sports medicine or stay incremental given ongoing execution pressures?
Compare Smith & Nephew SNATS Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Above median
Fair Value upside−3.1% · Above median
Profitability
Return on equity (12 months)11.9% · Top 25%
Return on assets6.0% · Above median
Net margin (12 months)10.1% · Above median
Operating margin (12 months)14.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)4.6% · Below median
Dividend yield (12 months)1.3% · Below median
Balance sheet
Debt / equity0.57× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)21.2× · Cheaper than median
P/B2.53× · Pricier than median
P/S (12 months)2.13× · Cheaper than median
Price / free cash flow (fiscal year)15.7× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Smith & Nephew SNATS Inc (SNN) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $30.19 versus a price of $31.15, about 3% lower (fairly valued).
What is the fair value of SNN?
Our model-based fair value for Smith & Nephew SNATS Inc is $30.19 (as of Nov 6, 2026), built from audited fundamentals. The current price: $31.15.
What is the quality score of SNN?
Smith & Nephew SNATS Inc has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Smith & Nephew SNATS Inc (SNN)?
Our model-based price target is the fair value of $30.19 (as of Nov 6, 2026) from 25 valuation models. Cautious scenario $18.71, optimistic scenario $41.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Smith & Nephew SNATS Inc stock forecast for 2026?
Our models put fair value at $30.19, about 3% lower versus a price of $31.15 (fairly valued). Cautious scenario $18.71, optimistic scenario $41.16. The calculation is refreshed regularly with new filings.
What is the revenue of Smith & Nephew SNATS Inc (SNN)?
Smith & Nephew SNATS Inc reported trailing-twelve-month revenue of about $6.3B (latest available figure, as of Nov 6, 2026).
Does Smith & Nephew SNATS Inc pay a dividend?
Smith & Nephew SNATS Inc currently shows a dividend yield of 1.27% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Smith & Nephew SNATS Inc (SNN) and when is the ex-dividend date?
Smith & Nephew SNATS Inc pays a dividend of $0.397 per share a year, a dividend yield of 1.3%. The last ex-dividend date was Oct 2, 2026. A dividend has been paid every year since at least 2000. The payout ratio is 27.0% of earnings. Free cash flow covers the dividend 5.14 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Smith & Nephew SNATS Inc (SNN)?
For today's price to be fair in a discounted-cash-flow model, Smith & Nephew SNATS Inc would have to grow free cash flow by +5.0 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of SNN use?
Our models discount Smith & Nephew SNATS Inc at 8.5 %: a base by market capitalisation (large), damped by beta 0.67, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Smith & Nephew SNATS Inc that is +5.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Smith & Nephew SNATS Inc (SNN) delivered so far?
Over the past 5 years revenue at Smith & Nephew SNATS Inc grew +6.3 % a year. The price currently implies free-cash-flow growth of +5.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Smith & Nephew SNATS Inc (SNN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Smith & Nephew SNATS Inc (+5.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Smith & Nephew SNATS Inc (SNN)?
The free-cash-flow yield on the price is 6.37 %: that much free cash flow Smith & Nephew SNATS Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Smith & Nephew SNATS Inc (SNN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Smith & Nephew SNATS Inc it is $30.19 per share (as of Nov 6, 2026), against a price of $31.15. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Smith & Nephew SNATS Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, SNN trades above its calculated fair value: price $31.15, fair value $30.19, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SNN?
No. The price is what the market pays today ($31.15); the fair value is what the company's own numbers justify ($30.19). For Smith & Nephew SNATS Inc the two are $0.9600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Smith & Nephew SNATS Inc worth?
The market values Smith & Nephew SNATS Inc at about $13.4B (market capitalisation, as of Nov 6, 2026). Per share that is $31.15; our models calculate a fair value of $30.19 per share.
What do the bullish and bearish scenarios say about SNN?
Our models span a range for Smith & Nephew SNATS Inc: cautious scenario $18.71, base $30.19, optimistic $41.16 per share (as of Nov 6, 2026, price $31.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SNN?
Smith & Nephew SNATS Inc trades at a price-to-earnings ratio of 21.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $30.19 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 25.4. Other multiples: PEG 1.1, P/B 2.5, P/S 2.1, EV/EBITDA 11.5.
What is the PEG ratio of SNN?
The PEG ratio of Smith & Nephew SNATS Inc is 1.05 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Smith & Nephew SNATS Inc (SNN)?
Balance-sheet figures for Smith & Nephew SNATS Inc (as of Nov 6, 2026): return on equity 11.9%, debt of 0.57 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is SNN from its 52-week high?
Smith & Nephew SNATS Inc trades at $31.15, about 13% below its 52-week high of $35.92 and 19% above the low of $26.27 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $30.19 is for.
Which stocks are comparable to Smith & Nephew SNATS Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Smith & Nephew SNATS Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $31.15, calculated fair value $30.19 (−3%), Quality Score 63/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SNN calculated?
We run Smith & Nephew SNATS Inc through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $30.19 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Smith & Nephew SNATS Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Smith & Nephew SNATS Inc (SNN)?
The closing price on Nov 6, 2026 was $31.15. Our model-based fair value is $30.19, about 3% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Smith & Nephew SNATS Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($18.71 to $41.16) leaves room in how you read the outcome.
Where does the earnings growth of Smith & Nephew SNATS Inc (SNN) come from?
Earnings per share at Smith & Nephew SNATS Inc grew −0.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.9 %, EBIT margin −3.0 %, tax rate +1.5 %, residual (interest, one-offs) −3.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Smith & Nephew SNATS Inc
How large is the market capitalisation of Smith & Nephew SNATS Inc (SNN)?
The market capitalisation of Smith & Nephew SNATS Inc is $13.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Smith & Nephew SNATS Inc (SNN)?
The price-to-sales ratio of Smith & Nephew SNATS Inc is 2.15 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Smith & Nephew SNATS Inc (SNN)?
Earnings per share at Smith & Nephew SNATS Inc are $1.47 (price ÷ EPS = P/E 21.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Smith & Nephew SNATS Inc (SNN)?
The dividend yield of Smith & Nephew SNATS Inc is 1.3% (payout 27.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Smith & Nephew SNATS Inc (SNN)?
The net margin of Smith & Nephew SNATS Inc is 10.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Smith & Nephew SNATS Inc (SNN)?
The return on equity (ROE) of Smith & Nephew SNATS Inc is 11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Smith & Nephew SNATS Inc (SNN)?
On an EBIT basis the return on assets of Smith & Nephew SNATS Inc is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Smith & Nephew SNATS Inc (SNN)?
The operating margin of Smith & Nephew SNATS Inc is 14.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Smith & Nephew SNATS Inc (SNN)?
Revenue at Smith & Nephew SNATS Inc is growing +4.6% versus a year earlier (3y avg +5.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Smith & Nephew SNATS Inc (SNN)?
Earnings per share at Smith & Nephew SNATS Inc are growing +5.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Smith & Nephew SNATS Inc (SNN) carry?
The net debt of Smith & Nephew SNATS Inc is $2.8B (fiscal year 2025, ≈ 3.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Smith & Nephew SNATS Inc in the live analysis
One click puts Smith & Nephew SNATS Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026